NCT01176097View on ClinicalTrials.gov

To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Type 2 Diabetes
Interventions
DRUG

AZD5658

oral suspension, escalating single doses

DRUG

Placebo

oral suspension,single doses

Trial Locations (1)

Unknown

Research Site, Chula Vista

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT01176097 - To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes | Biotech Hunter | Biotech Hunter